Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FT500
- Development stage
- Phase 1
- Lead developer
- Fate Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
FT500 is an investigational, off-the-shelf allogeneic natural killer (NK) cell immunotherapy derived from a clonal master induced pluripotent stem cell (iPSC) line. Developed as a universal NK cell product, it is designed to be administered to patients without the need for patient-specific customization. Upon administration, the iPSC-derived NK cells bind to stress-induced ligands on tumor cells, leading to tumor cell lysis and release of tumor neoantigens. This mechanism bridges innate and adaptive immunity and has potential to overcome resistance mechanisms associated with immune checkpoint inhibitors. The therapy was developed by Fate Therapeutics in collaboration with the University of Minnesota for use in advanced solid tumors and other malignancies[1][2][4][5][8].
- Other names
- iPSC-derived natural killer cells FT500
Beyond the preview
Go deeper on FT500.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FT500.